Status:
RECRUITING
Probiotics in Mild Alzheimer's Disease
Lead Sponsor:
University of Nicosia
Collaborating Sponsors:
Cyprus Institute of Neurology and Genetics
Conditions:
Neurodegenerative Diseases
Cognition Disorders in Old Age
Eligibility:
All Genders
65-85 years
Phase:
EARLY_PHASE1
Brief Summary
The main objective is to investigate whether administration of probiotics to patients with mild Alzheimer's Disease (AD) reduces neuroinflammation, improves cognitive function and modifies neurophysio...
Detailed Description
We will measure specific blood inflammatory markers (primary outcome), neurophysiological activity, cognitive test scores, microbiome composition and dietary habits of participants in the probiotics a...
Eligibility Criteria
Inclusion
- Adults ≥65 years, able to give consent
- Mini-Mental State Examination (MMSE) scores 19-23 (mild AD)
- approximately equal male:female ratio
Exclusion
- Inability to give consent
- other neurological disease
- relevant psychiatric disorders (e.g. major depression)
- gastrointestinal/metabolic conditions
- history of alcohol/substance dependence
- use of systemic antibiotics in the previous 6 months
- corticosteroid use
- immune stimulating medications
- immunosuppressive agents
- probiotics consumption in the previous 6 months.
- immunosuppression
- structural heart disease
- neutropenia
- radiation
- active intestinal disease
Key Trial Info
Start Date :
December 19 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06181513
Start Date
December 19 2022
End Date
December 1 2025
Last Update
December 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Cyprus Institute of Neurology and Genetics
Nicosia, Cyprus